医学
表皮生长因子受体
肺癌
肿瘤科
酪氨酸激酶抑制剂
酪氨酸激酶
内科学
表皮生长因子受体抑制剂
癌症研究
表皮生长因子
受体
癌症
作者
Huaiyu Wang,Fan Zhang,Xiaoming Yang,Qing Wu,Suxin Jiang,Jianguo Zhu,Jie Liu,Chuanhong Zhou,Yinghui Liu,Xia You,Yuexin Han
标识
DOI:10.1093/oncolo/oyad339
摘要
Abstract Sequential regimens in patients with epidermal growth factor receptor (EGFR) mutation-positive non–small cell lung cancer (NSCLC) can overcome tyrosine kinase inhibitor (TKI) resistance and maximize clinical benefit. Patients with advanced NSCLC can achieve excellent tumor control after a period of EGFR-TKI treatment. Patients may benefit from additional local treatment, such as surgery or radiation therapy, once the tumor is under control. Here, we present a case of a patient with advanced oligometastatic NSCLC with EGFR mutations who achieved downstaging through sequential EGFR-TKI-based precision medicine allowing resection of residual disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI